KR20210131039A - Composition of Nutrient Delivery System for Improving Brain Function - Google Patents

Abstract

The present invention relates to a composition of nutrient delivery system for improving brain functions, including an extract of sialic acid of a swallow's nest as an active ingredient. According to an embodiment of the present invention, sialic acid as a brain function-improving substance, contained in a swallow's nest, is extracted efficiently through an affinity bead technology (ABT)-based sialic acid separation/purification process, and the thus extracted sialic acid extract is used as an active ingredient for improving brain functions. In addition, when micell nano-particles of a nutrient delivery system is added to the sialic acid extract extracted from a swallow's nest, the in vivo absorption ratio of the sialic acid extract is increased to provide an enhanced effect of improving brain functions.

Description

Nutrient delivery system for improving brain function {Composition of Nutrient Delivery System for Improving Brain Function}

The present invention relates to a nutrient delivery system composition used to improve brain function, and more particularly, to a nutrient delivery system composition for improving brain function comprising a sialic acid extract extracted from swallow's nest as an active ingredient.

Korea is facing a rapidly aging society, and therefore, an increase in cerebrovascular disorders or dementia is expected. For the prevention or treatment of these brain diseases, research and development of drugs having brain function improvement properties such as cerebral circulation, metabolism improving drugs, or anti-dementia drugs are in progress.

Recently, the search for substances that enhance brain functions such as learning ability and memory have been studied in various fields. In addition, from the viewpoint of prevention, substances that improve brain function that can be ingested through diet and the like are also required.

Swallow's nest is a nest made of saliva and feathers secreted by sea swallows. It is a traditional food that has been eaten since the Ming Dynasty in China. Swallow's nest contains sialic acid, which has been found to be effective in the treatment of Alzheimer's dementia by acting as an inhibitor of cholinesterase (AChE) and butyrylcholinesterase (BuChE). As swallowtail's nest is known through online distribution and home shopping at high-end Chinese restaurants and Chinese restaurants, interest and consumption as various processed foods and ingredients are rapidly increasing, but most of them are simple dried products and processed products. There is an urgent need for development of an extraction method for efficiently extracting functional substances, that is, substances for improving brain function, and development of a composition including substances for improving brain functions extracted by this extraction method is urgently required.

Republic of Korea Patent Publication No. 10-2016-0007708 (published on January 21, 2016) Republic of Korea Patent No. 10-0569089 (Registration Date 2006.04.03)

The present invention has been devised to solve the problems of the prior art,

An object of the present invention is to efficiently extract sialic acid, a brain function improving substance contained in swallow's nest, by a method for separating and purifying sialic acid based on ABT (Affinity Beads Technology), and including the sialic acid extract extracted by the above method as an active ingredient To provide a nutrient delivery system composition for improving brain function.

Another object of the present invention is to provide a nutrient carrier composition for improving brain function that increases the brain function improvement effect by adding a nutrient carrier of micellar nanoparticles to a sialic acid extract extracted from swallow's nest to increase the absorption rate of the sialic acid extract in the body. there is

The nutrient delivery system composition for improving brain function according to an embodiment of the present invention, which is provided to achieve the above object, is characterized in that it contains the sialic acid extract of swallow's nest as an active ingredient.

Here, the step of extracting the sialic acid extract by adding one or more solvents selected from the group consisting of water, alkaline ionized water or an organic solvent to the swallow's nest; adsorbing sialic acid by adding non-polar polymer beads to the extracted solvent; separating the non-polar polymer beads to which the sialic acid is adsorbed and desorbing the sialic acid by adding a desorbent thereto; It is characterized in that the extraction is performed by an ABT (Affinity Beads Technology)-based sialic acid separation and purification method comprising a; solidifying the desorbed sialic acid.

And, the sialic acid extract of the swallow's nest is characterized in that it further comprises a nutrient delivery system that increases the absorption rate in the body, and the nutrient delivery system is characterized in that the micelle nanoparticles.

In addition, the sialic acid extract of the swallow's nest contains brain function improving substances alpha-GPC, soybean lecithin, DHA, phosphatidylserine, broccoli, Angelica keiskei, daffodils, longan meat, ginseng, maekmundong, cheonma, ginkgo leaf extract, royal jelly, Reishi, Korean ginseng, chlorella, brown rice black vinegar, propolis, sesamin, characterized in that any one or two or more selected from turmeric is further included.

According to an embodiment of the present invention, sialic acid, a brain function improving substance contained in swallow's nest, is efficiently extracted by ABT (Affinity Beads Technology)-based sialic acid separation and purification method, and the sialic acid extract extracted by the above method is effective By including it as an ingredient, it has the effect of improving brain function.

In addition, the nutrient delivery system of micellar nanoparticles is added to the sialic acid extract extracted from the swallow's nest to increase the absorption rate of the sialic acid extract in the body, thereby increasing the brain function improvement effect.

1 is a process diagram illustrating a method for separating and purifying sialic acid based on ABT (Affinity Beads Technology) in a nutrient delivery system composition for improving brain function according to an embodiment of the present invention.
2 is a conceptual diagram for explaining fast-acting micellar nanoparticles containing bile acid and sialic acid in the nutrient delivery system composition for improving brain function according to an embodiment of the present invention.
3 is a graph comparing the efficacy of bird's nest extract and sialic acid on AChE activity in the nutrient delivery system composition for improving brain function according to an embodiment of the present invention.
Figure 4 is a comparison of cell degeneration of the group treated with amyloid beta protein in the ventricle and the group not treated with anything in order to observe the degree of degeneration of neurons in the hema region in the nutrient delivery system composition for improving brain function according to an embodiment of the present invention; image.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The following detailed description of the present invention is an embodiment in which the present invention may be practiced, and reference is made to the accompanying drawings shown by way of example for the embodiment. These embodiments are described in sufficient detail to enable those skilled in the art to practice the present invention. It should be understood that various embodiments of the present invention are different but need not be mutually exclusive. For example, certain shapes, structures, and characteristics described herein may be implemented in other embodiments without departing from the spirit and scope of the invention with respect to one embodiment. It should also be understood that the position or arrangement of individual components in each described embodiment may be changed without departing from the spirit and scope of the present invention.

Accordingly, the detailed description set forth below is not intended to be taken in a limiting sense, and the scope of the present invention, if properly described, is limited only by the appended claims, along with all scopes equivalent to those claimed by the claims. Like reference numerals in the drawings refer to the same or similar functions throughout the various aspects.

The terms used in the present invention have been selected as currently widely used general terms as possible while considering the functions in the present invention, but these may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, and the like. In addition, in specific cases, there are also terms arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the corresponding invention. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than the name of a simple term.

In the whole of the invention, when a part "includes" a certain element, it means that other elements may be further included, rather than excluding other elements, unless otherwise stated. Also, terms such as “…unit” and “…module” described in the specification mean a unit that processes at least one function or operation, which may be implemented as hardware or software, or a combination of hardware and software.

The nutrient delivery system composition for improving brain function according to an embodiment of the present invention uses sialic acid extract contained in swallow's nest as an active ingredient.

Here, the nest itself or a small piece of the nest, dried and powdered, or a bird's nest extract or a bird's nest concentrate or a bird's nest extract powder or a suspension thereof, etc. may be used as a raw material.

The components contained in this bird's nest include sialic acid derivatives, such as N-acyl and its derivatives of neuraminic acid, N-acetylneuraminic acid (Neu5Ac) and N-glycolneuraminic acid (Neu5Gc), and hydroxylamide. There are derivatives in which the actual group is modified with an acetyl group, a sulfuric acid group, a phosphoric acid group, or the like.

And, the sialic acid contained in the swallow's nest has a neuraminic acid skeleton represented by the following general formula.

[Formula 1]

Sialic acid, a brain function improving substance contained in the swallow's nest, is extracted by ABT (Affinity Beads Technology)-based sialic acid separation and purification method.

As shown in FIG. 1, in the ABT (Affinity Beads Technology)-based sialic acid separation and purification method, first, swallow's nest is extracted by adding one or more solvents selected from the group consisting of water, alkaline ionized water, or an organic solvent.

Then, non-polar polymer beads are added to the extracted solvent to adsorb sialic acid.

Then, after separating the non-polar polymer beads to which the sialic acid is adsorbed, a desorbent is added thereto to desorb the sialic acid.

Then, the desorbed sialic acid is solidified.

At this time, if it is desired to obtain a bird's nest extract containing a large amount of sialic acid, it is preferable to use SEPHADEXLH-20 (manufactured by Amersham pharmacia Biotech AB: Cat17-0090-01) as a column.

The chromatogram of the thus-obtained extract by HPLC (high-performance liquid chromatography) was compared with the sialic acid chromatogram of the standard product, and it was confirmed that the extract contained a sialic acid derivative.

In addition, the sialic acid extract of swallow's nest may contain a nutrient carrier that increases the absorption rate in the body.

Nutrient Delivery System is a term used in the food industry, and it is a system that effectively delivers nutrients such as sialic acid to necessary organs. Similar examples include a drug delivery system in the pharmaceutical industry and a transdermal delivery system in the cosmetic industry, which is a delivery system that absorbs and delivers a specific drug or cosmetic material into the body.

As such, the nutrient delivery system plays a role in increasing the absorption rate of nutrients in the body, considering that most nutrients are absorbed into the body and are not easily delivered to specific organ tissues or cells, making it difficult to deliver their efficacy to the organs as much as possible.

As shown in FIG. 2 , the nutrient carrier is a fast-acting micelle nanoparticle having excellent absorption rate and efficacy in the body when bile acid is used. Here, the bile acid and the sialic acid are connected as shown in FIG. 2 . And, the micellar nanoparticles have a size of 100 to 200 nm, preferably have a size of 110 to 190 nm, more preferably have a size of 120 to 180 nm. The micellar nanoparticles, which are nutrient carriers having the above size, facilitate penetration and absorption of tissues in the body, thereby increasing the absorption rate of sialic acid in the body. Due to this, the effect of improving brain function, which is the efficacy of sialic acid, is increased.

In addition, micellar nanoparticles, which are nutrient carriers, have high tissue permeation and absorption rates by including lyzolecithin as a surfactant.

In addition, the sialic acid extract of swallow's nest contains brain function improving substances such as alpha-GPC, soybean lecithin, DHA, phosphatidylserine, broccoli, angelica, daffodil, longan meat, ginseng, maekmundong, cheonma, ginkgo leaf extract, royal jelly, Reishi, Korean ginseng, chlorella, brown rice black vinegar, propolis, sesamin, any one or two or more selected from turmeric may be further included.

In addition, excipients, sweeteners, acidulants, thickeners, fragrances, colorants, emulsifiers, and other additives or materials commonly used in pharmaceuticals or foods, etc. may be included within the range that does not impair the effect of sialic acid.

[Example 1]

Hereinafter, the present invention will be described in more detail with reference to Preparation Examples, Formulation Examples, Test Examples, and the like, but the present invention is not limited thereto. In particular, although examples are shown here without dividing the swallow's nest of the present invention into fermented and non-fermented, fermented swallow's nest may also be used.

The swallow's nest used was made from swallow's nest extract sold under the trade name The King's Morning manufactured by Natural Ltd, Thailand. This swallow's nest extract had sialic acid as shown in Table 1. In addition, the useful ingredients were collagen, sialic acid, polyphenol, calcium, iron, and dietary fiber, and the binding sugars were only galactose and arabinose. The swallow's nest used was 42.5% acetyl and 27.5% keto, which contained a lot of acetyl sialic acid.

designation Dissolution time (min) range(%) content Acetyl-galactoside 8.75 13.72 go Acetyl-Glucoside 10.84 15.23 go Acetyl-arabinoside 12.53 12.72 go Keto-galactosides 15.17 5.17 cow Keto-Glucoside 17.52 6.83 middle Keto-arabinoside 20.38 3.52 cow

1. Preparation of bird's nest extract and sialic acid extract and preparation of nutrient delivery system (Preparation Example 1)

The bird's nest extract obtained by pulverizing the nest with purified water and extracting it was adsorbed on a Sep-Pac Plus C18 Cartridge column (manufactured by Waters), washed with sterile water, and eluted with 1% HCI-methanol solution to extract sialic acid in the nest. has been separated The sialic acid extract thus obtained was concentrated by an evaporator at a temperature of 37°C, the pH was adjusted to 7.0, dissolved in DMSO (dimethyl sulfoxide), and then dried to obtain a bird's nest extract and a sialic acid extract. In addition, if it is desired to obtain a bird's nest extract containing a large amount of sialic acid, it may be prepared by the ABT method using SEPHADEXLH-20 (Amersham pharmacia Biotech AB, Cat17-0090-01) as a column.

A nutrient carrier, that is, micellar nanoparticles, 5.78 g of taurocholic aicd was mixed with 25 ml methanol (methanol 85: water 15 volume ratio) to make a 430 mM taurocholic acid solution. A first solution was prepared by adding 1.8 mL of a lecithin solution (a lecithin solution dissolved in chloroform at 100 mg/mL in chloroform) to 2.25 mL of the taurocholic acid solution. The prepared primary solution was placed in a glass tube with a Teflon cap and heated in a 55° C. water bath for 5 hours. Then, the first solution was evaporated using nitrogen gas until it became sticky and thick and yellowish. The evaporated residue was frozen at -70°C for 2 hours, opened the tube, and lyophilized under reduced pressure for more than 9 hours, then dissolved in PBS and heated at 56°C for 4 hours. After the heat treatment was completed, the solution was diluted 1:10 in serum-free medium (by volume) and filtered using a 0.45um filter to prepare sialic acid-bile acid conjugated micellar nanoparticles.

2. Preparation of test formula

Formulation Example 1 and a placebo formula were prepared as test formulas by filling the compounding ingredients into a soft capsule (OVAL No. 6) according to a conventional method based on the following prescription.

Composition of test formula (in 1 capsule) Ingredients Formulation Example 1 (mg) Flavo formula (mg) Preparation Example 1 (Nutrition delivery system) 130.5 0 rapeseed oil 195.3 325.8 Vegetable Meatloaf 34.2 34.2 Sum 360.0 360.0

The capsule shell is made of gelatin powder, glycerin, titanium dioxide, and caramel pigment.

3. Subject

Subjects were those who did not meet the following exclusion criteria among men and women aged 50 to 70 who had conducted a lifestyle questionnaire survey before the test.

Exclusion criteria:

a) A person who is already using swallow's nest

b) A person who regularly uses drugs or health supplements containing swallow's nest as a main ingredient

c) Those who are taking medicines or health supplements that affect brain function or blood circulation

d) Those with diabetes or serious diseases such as brain function, blood circulation, digestive system, pancreas, liver or kidney

e) Those who are participating in another clinical trial at the start of this trial

f) Persons with certain allergies (including swallow's nest)

g) A person judged unsuitable as a test subject from the results of the lifestyle questionnaire survey (for example, a person who has ever caused an allergy to an ingredient in the test formula, a person with an extreme tendency to drink, etc.)

h) Persons with color vision abnormality or color vision impairment

i) Others, those judged by the examination doctor to be inappropriate

4. Exam Schedule

The trial was performed as a double-blind, parallel-group comparison.

First, the subject was brought to the hospital on the first day of the test period (the first day of the test), and questionnaires, physical measurements, and brain function tests 1 and 2 were performed.

Then, these subjects were randomly divided into two groups of a test group and a placebo group, 30 each, and ingestion of the test food was started.

The subjects in the test group were given Formulation Example 1, and the subjects in the placebo group were given a placebo meal, respectively, once daily, 2 capsules, for 12 weeks. In addition, subjects were asked to keep a journal while feeding.

After the start of feeding, the questionnaire, physical measurement, and brain function test 2 were performed 4 weeks (test day 28), 8 weeks (test day 56), and 12 weeks (test day 84), respectively.

5. Inspection items

In this test, questionnaires, physical measurements, and brain function tests were performed. Each inspection method was as follows. In addition, the values obtained in each test were expressed as the average value ㅁ standard error.

a) Paperweight

The presence or absence of subjective symptoms and subjective symptoms was asked.

b) body measurements

Height, weight, body fat, blood pressure, pulse rate, and visual acuity were measured.

c) brain function test

As a brain function test, the following brain function tests 1 and 2 were performed. The test was done on an empty stomach. Also, smokers were banned from smoking until the test was completed.

Brain function test 1: The test was conducted using the revised Hasegawa Simple Intelligence Assessment Scale (HDS-R).

Brain function test 2: It was tested by the recall test of words and the Stroop test. Each test was performed as follows.

(1) Recall test of words

"Tell me as many animal names as you know" was said to the subject, followed by listing the names of animals that could be enumerated within 60 seconds of the first animal name being mentioned. The number of animal names listed, excluding duplicates, was recorded and counted as the number.

When the first animal could hardly be remembered, the subject was induced by saying, "For example, dog is the name of an animal, what else is there?" If 30 seconds had elapsed without recalling even after this induction, the test was stopped and the above count was set to zero.

Animals are not limited to mammals, and names of reptiles, birds, fish, etc. are also added to the above number.

Similarly, vegetables and words beginning with "ah" were listed respectively, and their recalls were recorded.

In addition, the said number of each of these animals, a vegetable, and a horse beginning with "ah" was totaled, and this was made into the total number.

(2) Stroke test:

A test in which 70 characters of three colors of “red”, “blue” and “black” are randomly written (step 1),

Examination of reading 70 colors of 3 types of "red", "blue" and "black" (step 2), and 70 characters written in "red", "blue" and "black" of "red", "blue" and "black" The colors were randomly classified into three types, and a total of four tests, a test for reading the character (step 3) and a test for reading the color (step 4), were performed, and the number of seconds required for reading was recorded.

a) journal

The subjects were asked to describe the intake status of the test food, subjective symptoms, and the status of taking other medicines.

6. Test results

a) the background of the subject

In the placebo group and the test group, 25 and 25 subjects (50 total), respectively, participated in the trial, but no one dropped out or stopped. Table 3 shows the background of the subjects who participated in the test. There was no disparity between groups in scores by age, sex, and HDS-R.

(P>0.05). In addition, statistical analysis was carried out by analysis of variance (ANOVA).

subject's background army placebo group test group gender male 12 12 female 13 13 Average age (years) 60.5 ± 1.25 60.3 ± 1.27 Average score by HDS-R 28.5 ± 0.23 29.5 ± 0.25

Value: mean ± standard error

b) validity

The first day of the exam, the 28th. The effectiveness on brain function of Formulation Example 1 was evaluated from the measured values of the brain function test 2 of the subjects on the 56th day and the 84th day.

Statistical interpretation was tested by the corresponding within-group t-test when comparing the first day of the test and the 28th, 56th, and 84th days of the test within the same group. The significance level was set to 5% on both sides.

c) brain function test

(1) Recall test of words

In the test group, the counts and total counts of animals, vegetables, and horses beginning with "ah" were increased compared to before ingestion (Table 4), but no increase was seen in the placebo group.

(2) strobe test

In the test group, the number of seconds required to read each step of steps 1 to 4 decreased (Table 5), but no decrease was seen in the placebo group.

As described above, the effect was not clearly recognized in the placebo group, and the brain function improvement effect of Formulation Example 1 was clear.

Action of test formula on brain function (remembering test of words) Metrics the first day of the exam test week 4 Week 8 of the exam Week 12 of the exam vegetable 17.36 ± 0.53 17.79 ± 0.67 19.23 ± 0.69 21.37 ± 0.68 Words that start with "a" 12.86 ± 0.75 15.68 ± 0.34 16.87 ± 0.85 18.2 1± 0.85 animal 19.33 ± 1.22 23.67 ± 0.93 22.78 ± 1.17 22.25 ± 1.15 total number 49.55 ± 2.50 57.14 ± 1.94 58.88 ± 2.71 61.83 ± 2.68

Unit: dog

Value: mean ± standard error

Action on brain function of test formula (Stroke test) Metrics the first day of the exam test week 4 Week 8 of the exam Week 12 of the exam Step 1 32.89 ± 1.28 31.92 ± 1.25* 32.22 ± 1.21 30.75 ± 1.32 Step 2 35.73 ± 1.36 33.45 ± 1.37 36.72 ± 1.38 35.21 ± 1.28 Step 3 42.18 ± 1.25 38.58 ± 1.56 40.35 ± 1.69 37.87 ± 1.35 Step 4 60.17 ± 2.19 55.38 ± 2.51 56.39 ± 2.17 53.86 ± 2.17

Unit: Seconds

Value: mean ± standard error

Step 1: The number of seconds required to read the character, Step 2: The number of seconds required to read the color, Step 3: The number of seconds required to read the colored text, Step 4: The number of seconds required to read the colored text.

d) safety

There were no abnormalities in body weight, blood pressure and pulse. There were no abnormal findings in the diary. In addition, no harmful matters related to the test formula were observed during this test period.

From the above, it can be said that the formulation is safe with a value of 1.

[Example 2]

1. Comparison of Efficacy of Bird's Nest Extract and Sialic Acid on AChE Activity

A comparative experiment on AChE activity was conducted using the swallow's nest extract and sialic acid as follows. As an experimental animal, a 5-week-old male ICR mouse (Orient Bio, Korea) was purchased and an adaptation period of one week was maintained. In order to compare the effect of inhibiting AChE activity in vivo, a control group (Donepezil 1.0mg/kg) and sialic acid (200mg/kg) and bird's nest extract (50mg/kg) were orally administered to each mouse (3 mice in each group) once. did. Six hours after administration of each substance, the hippocampus was isolated and homogenized using 1 M phosphate buffer (pH 8.0) to obtain a homogenate. The obtained homogenate was measured for AChE activity in vivo using Amplex red assay kit (Molecular probe, USA). As a result, in the case of the bird's nest extract, the inhibitory effect on AChE activity was insignificant, whereas in the case of sialic acid, about 71.5% of the inhibitory effect on AChE activity was observed (see FIG. 3 ).

2. Histological examination of hippocampus in amyloid beta protein-induced dementia rat model

After the behavioral examination was completed, the rats were anesthetized with diethyl ester, and the abdominal cavity was opened and perfused with saline through the heart. Then, the brain was extracted and fixed in 10% neutral buffered formalin, and the degree of degeneration of the nerve cells in the hippocampus was observed through hematoxylin & eosin staining. As a result, in the group treated with amyloid beta protein in the ventricle, deterioration of pyramidal cells related to memory in the dentate gyrus of the hippocampus was observed compared to the group not treated with anything. In the group administered with sialic acid at a concentration of 200 mg/kg for 4 weeks, the degree of damage was weak (see FIG. 4 ).

As described above, the present invention is useful for the prevention and treatment of brain dysfunction. Here, the brain dysfunction includes dementia such as cerebrovascular dementia, Alzheimer's type dementia, and a mixture of both; memory loss, such as forgetfulness or amnesia; cognitive decline; poor learning ability; Meniere's disease and subarachnoid hemorrhage (meningoencephalopathy), cerebral hemorrhage, cerebral thrombosis, cerebral infarction, and sequelae of cerebrovascular disorders such as cerebral edema (impairment of consciousness, movement and speech disorders due to restlessness, speech disorders, aphasia, emotional disorders, accidents) impairment, sensory impairment, memory impairment, and postural abnormality) and the like.

In addition, the present invention is Alzheimer's type dementia; Meniere's disease; and subarachnoid hemorrhage, cerebral hemorrhage and sequelae of cerebral infarction.

In addition, the present invention can be used not only for the purpose of preventing and treating brain dysfunction, but also for the purpose of further improving brain functions such as learning ability, memory or reflex response ability of a healthy person.

In addition, the present invention can be used as a food or animal feed, for example, as a health food, a functional food, a health supplement, a food for specific health use, a beauty food, or a nutritional supplement (supplement). These foodstuffs and animal feeds include, for example, beverages such as tea and juice; and ice cream, jelly, candy, chocolate, and chewing gum. In addition, it may be in the form of a liquid, powder, granule, capsule, or tablet. Here, the animal feed for animals includes all animals that require the prevention or treatment of edema, including pet livestock animals or animals raised in zoos, etc.

In addition, the present invention can be used as a pharmaceutical or quasi-drug. These pharmaceuticals or quasi-drugs can be administered orally in the form of, for example, powder, tablet, coated tablet, dragee, hard or soft gelatin capsule, solution, emulsion, or suspension, for example, in the form of a suppository. rectally, for example, in the form of an injection or lubricating fluid; For example, it may be administered parenterally or topically in the form of an ointment, cream, gel, or solution. Preferred is oral administration.

In addition, when the present invention is used in the form of a tablet, various carriers cited in pharmaceutical or food science can be used, and excipients such as lactose and glucose, binders such as water and ethanol, and boron such as agar powder and dry starch Disintegration inhibitors such as release, stearin and cacao butter, adsorbents such as kaolin and bentonite, absorption accelerators such as sodium lauryl sulfate, humectants such as glycerin and starch, lubricating agents such as boric acid malt and polyethylene glycol, and the like can be exemplified.

In addition, the intake amount of the present invention is not particularly limited, but may be appropriately selected according to the dosage form and the age, weight, and symptoms of the ingester or the ingested animal such as the user or patient. For example, excellent brain function improvement by oral intake of 0.3 to 5 mg, preferably 0.35 to 3 mg, more preferably 0.35 to 1.5 mg of sialic acid per 1 kg of body weight of the ingestor or ingested animal per day as an active ingredient It is preferable because the effect can be obtained. In addition. The ingestion period can be arbitrarily determined according to the age and symptoms of the ingestor or animal.

As described above, the present invention efficiently extracts sialic acid, a brain function improving substance contained in swallow's nest, by using ABT (Affinity Beads Technology)-based sialic acid separation and purification method, and includes the sialic acid extract extracted by the above method as an active ingredient By doing so, it is useful not only to improve brain function, but also to prevent and treat brain dysfunction. In addition, the nutrient delivery system of micellar nanoparticles is added to the sialic acid extract extracted from the swallow's nest to increase the absorption rate of the sialic acid extract into the body, thereby improving brain function and preventing and treating brain dysfunction. In addition, even if it is taken for a long time, there is little worry about side effects and the like, and the safety is high. And, it can be used as food, such as a pharmaceutical or health food, a health supplement, a food for specific health use, or a nutritional supplement.

Although preferred embodiments of the present invention have been described above, the present invention is not limited to the specific embodiments described above. That is, a person of ordinary skill in the art to which the present invention pertains can make numerous changes and modifications to the present invention without departing from the spirit and scope of the appended claims, and all such appropriate changes and modifications are Equivalents are to be considered as falling within the scope of the present invention.

Claims (5)

A nutrient delivery system composition for improving brain function comprising the sialic acid extract of swallow's nest as an active ingredient. The method of claim 1,
The step of extracting the sialic acid extract by adding one or more solvents selected from the group consisting of water, alkaline ionized water, or an organic solvent to the swallow's nest; adsorbing sialic acid by adding non-polar polymer beads to the extracted solvent; separating the non-polar polymer beads to which the sialic acid is adsorbed and desorbing the sialic acid by adding a desorbent thereto; A nutrient delivery system composition for improving brain function, characterized in that it is extracted by an ABT (Affinity Beads Technology)-based sialic acid separation and purification method comprising a step of solidifying the desorbed sialic acid. The method of claim 1,
A nutrient delivery system composition for improving brain function, characterized in that the sialic acid extract of the swallow's nest further includes a nutrient delivery agent that increases absorption into the body. 4. The method of claim 3,
The nutrient delivery system is a nutrient delivery system composition for improving brain function, characterized in that the micellar nanoparticles. The method of claim 1,
The sialic acid extract of the swallow's nest includes brain function improving substances alpha-GPC, soybean lecithin, DHA, phosphatidylserine, broccoli, Angelica keiskei, daffodils, longan meat, ginseng, maekmundong, cheonma, ginkgo leaf extract, royal jelly, reishi, Korean ginseng, chlorella, brown rice black vinegar, propolis, sesamin, nutrient delivery system composition for improving brain function, characterized in that it further comprises any one or two or more selected from turmeric.

Images